Heart failure is the leading cause of hospitalization and death globally. AnaCardio is a biotech company in the clinical stage that is developing a small molecule pharmaceutical with a novel potential first-in-class treatment option. Based on world-leading research from Karolinska Institutet leading to the discovery of a disease-modifying mechanism they provide a unique approach with the potential to save millions of lives. ↗